KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash from Operations (2016 - 2025)

Nektar Therapeutics has reported Cash from Operations over the past 16 years, most recently at 64959000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 64959000.0 for Q4 2025, down 40.64% from a year ago — trailing twelve months through Dec 2025 was 208511000.0 (down 18.67% YoY), and the annual figure for FY2025 was 208511000.0, down 18.67%.
  • Cash from Operations for Q4 2025 was 64959000.0 at Nektar Therapeutics, down from 48761000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for NKTR hit a ceiling of 37702000.0 in Q2 2024 and a floor of 151538000.0 in Q4 2021.
  • Median Cash from Operations over the past 5 years was 51719000.0 (2023), compared with a mean of 64674650.0.
  • Biggest five-year swings in Cash from Operations: crashed 92.0% in 2021 and later surged 61.92% in 2022.
  • Nektar Therapeutics' Cash from Operations stood at 151538000.0 in 2021, then soared by 61.92% to 57703000.0 in 2022, then increased by 18.47% to 47047000.0 in 2023, then rose by 1.83% to 46187000.0 in 2024, then crashed by 40.64% to 64959000.0 in 2025.
  • The last three reported values for Cash from Operations were 64959000.0 (Q4 2025), 48761000.0 (Q3 2025), and 45738000.0 (Q2 2025) per Business Quant data.